Member Info for Luckenbach

Well, I’ll take this positive. Long term positive. A CEO shouldn’t be manipulating SP and he isn’t. He does not have to buy more shares in such a minor amount compared to his stake. At the moment he can’t do this in case he has significant insider information? So the learning here is that he has a long term confidence on their future. And then he should continue buying. Otherwise I do not understand unless there are grand children getting shares as a donation? (I don’t know their family)

Meds just don’t want to start using Traumakine but prefer steroids to interferon beta for COVID because it’s only few dollars instead of 2 grands for Traumakine? (Benefits not proven). Faron invented up-regulating CD73 to protect organs but not interferon beta itself. Not meaning that this all not been great work, but some fundamental resistance against Interferon beta as a treatment developed by small biotechs? Sometimes drugs get approved by FDA but no one will use as a treatment, many reasons…not well tolerated, difficult to administer, too fragmented market, no resources to promote, competition…

Traumakine will be appreciated in organ protection we’ll see, do not sell it cheap. Sell? Yes, otherwise on the shelf it goes off by itself, time will destroy it’s opportunities without developing it further. Who then if not Faron? Any close ones? BP?…

This simplifies things. Now it would be easier to spin out T and set price for the rest of the company (Bex). They have said they could even go to the very end with Bex all by themselves, without partnering. This does not close out a TO which IMO could be a very feasible alternative in this state of the world. Just to ensure patients do get a treatment for their cancers we do not want to risk that. Just as a short term scenario out of my mind.

Some positive Bex news at least expected soon because today we got this hibiscus news - news that was not forced to rns today?

Actually at AIM there is a company (FARN) Faron Pharmaceuticals Ltd. a biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. They know extremely well Interferon beta but has even better molecules to fight cancer.

I went through the Proactive interviews since 2018 and I have to say all that Markku has said they are believing and doing in their science is now having flesh on the bones. Corticosteroids, PNR, INFORAA, clever-1 etc all been mentioned since 2018 or 2019.

Markku has kept us well informed and now all three programs Traumakine, Clevegen and Hematokine are progressing well with proven concepts showing great clinical and commercial opportunities. Solid future plans.

To our shareholders luck Faron has not partnered or licensed anything yet although it was on the lips earlier. No doubt these programs are creating shareholder value.

Could be time for Motley Fool, Zacks etc. to start following and recommending for well balanced portfolios … to start with one or two grants at first! Could be a real banger even before US listing.

Thanks Sax!

Lap, I fully agree. You never know but I am trust fully in.

Laplom, a bid price can be based on a past SP, assets, future cash flow. In case major shareholders would accept anything you mentioned then maybe no big market for Faron’s drugs in the future. My opinion is the current level of SP has nothing to do with the future. Faron’s future market can be huge and so will be the SP IMO.

SNP rs9984273 is a relatively common polymorphism according to available data (REF: https://www.ncbi.nlm.nih.gov/snp/rs9984273#frequency_tab), carried by approximately 45% of people with African origin, 34% of Caucasians and 10% of Asians. This difference in the appearance of this SNP makes some populations much more vulnerable for steroid use.



"Endogenous interferon-beta production is one of the body's main first lines of defense against viral infection and it is widely hypothesized that dosing patients with interferon-based therapies can further strengthen this natural defense if given early enough," said Juho Jalkanen, M.D., Ph.D., Chief Operating Officer of Faron, and lead author of the newly published research. "However, our studies have shown that glucocorticosteroids can block this therapeutic effect and may have a potentially negative impact on patient survival."



"Our research also shows that a relatively common polymorphism, which until now has not been recognized as having any clinical significance, actually plays a critical role in disease states where interferons and glucocorticosteroids have an impact on mortality. These findings will support our continued research into the potential of intravenous interferon beta-1a therapy as a future treatment for ARDS and other acute settings of systemic inflammation leading to capillary leak."

Faron Publishes Research Identifying Gene Mutation in Interferon Receptor that Contributes to Corticosteroid Response and Outcome in ARDS and COVID-19 Patients



· Single nucleotide polymorphism identified during analysis of data from Phase III INTEREST trial of Traumakine

· Gene mutation in interferon alpha/beta receptor (IFNAR2) is associated with better outcomes among intravenous interferon beta-1a treated ARDS patients, irrespective of prior treatment with glucocorticosteroids

· Analysis of COVID-19 Host Genetics Initiative database indicates mutation is associated with less hospitalization for COVID-19

Well done! Looking bright for Faron with their programs and finance! The miserable times we are living at the brink of an era (not that climate change, sustainability, covid and strained economies wouldn’t be enough), Faron secures financing with an independent alternative financing provider. Well done for both I think. Faron has a bright future and IFP gets +9% and warrants for new shares. Not much lower than SP 3.126€ is expected any more (although now slightly below that). I think we are going to remember the 28th of Feb and the first of March as an inflection point in many ways. Upwards and onwards it should be! Hope so! What can we do?

The clouds are dark hanging above the world. The thoughts are in Ukraine. How much madness needs to be tolerated to avoid a big mess.

27 km long russian convoy lining up to attack Kiev? That must be a jiggery-pokery? Setting up as a target? A trap? “Raate Road”?

https://en.m.wikipedia.org/wiki/Battle_of_Raate_Road

Can it happen again? That would close a ring! I stand with you Ukraine!

Bex is in good hands!

I am confident!

Keep on hanging, although I don’t know how the structures will change. Something fundamental anyway is happening, I hope Ukrainian people will hold. Seems like we can’t give direct military support and help right now, only banning the enemy? Ukrainians will anyway help us by withstanding the enemy. Not to make it easy to the enemy means a lot to the rest of the world! I hope it’ll get as good as it can.

Can’t say all the best. That is what Stalin said to Finns before attacking Finland in 1939.

Getting listed in US could make more sense than ever before…

The Swiss Nordic one was postponed from Jan to March and was of course already earlier mentioned.

R&D day was great and Marie Louise’s first presentation made a very good impression, excellent!

I am very confident that Faron will succeed in many ways and a lot of news will come all along.

Like Markku mentioned in US this could be tenx. In other words I think the major 90% of the owners are saturated and satisfied to wait. Once and a while small investors need money and sell and when bigger sellers then luckily Timo buys if no one else. I guess soon also other wealthy buyers will spot this share and the company.

Great news! I believe this time even the SP can react, looks promising!

It’s been on talks here that Keytruda is a generally available drug for hospitals and for such possible for Faron to make their own studies with Bex combined with Pembrolizumab. Now that the start is postponed I only hope it is due Merck being interested too and giving their best support for a successful enrollment. I guess meds using Pembro does it anyway in close dialog with Merck?

I hope postponing the start of the trial doesn’t diminish the value of the R&D day tomorrow.

In case steroids were knowingly not a problem in SNG’s P2 and in case steroids are not the cause for failing P3 then there are two alternatives a) IFN beta doesn’t work or b) nebulize form or administration doesn’t work.

And if the reason is corticosteroids then It makes me wonder why this was allowed to happen? again!

Itsall, an other IFNbeta company gave an RNS this morning regarding the results of their P3 clinical trial. Failed!

Would be nice to have a series of tweets before the R&D day to increase the excitement :)